Product Description
By acting on HIF2_, DFF332 may be able to stop the growth of certain types of cancer.
Mechanisms of Action: HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, France, Italy, Japan, Singapore, Spain, Switzerland, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Renal Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04895748 |
CDFF332A12101 | P1 |
Active, not recruiting |
Renal Cell Carcinoma |
2026-03-06 |
12% |
2025-07-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
jRCT2031210239 |
jRCT2031210239 | P1 |
Recruiting |
Renal Cell Carcinoma |
2025-05-31 |
|||
2020-004383-25 |
2020-004383-25 | P1 |
Active, not recruiting |
Renal Cell Carcinoma |
2023-09-28 |
2025-05-06 |
Treatments |